Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation.
angiopoietin-2
hepatocellular carcinoma
immunocytochemistry
liver transplantation
neoangiogenesis
recurrence
survival
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
06
2022
accepted:
18
07
2022
entrez:
26
9
2022
pubmed:
27
9
2022
medline:
27
9
2022
Statut:
epublish
Résumé
Though the precise criteria for accessing LT are consistently being applied, HCC recurrence (HCC-R_LT) still affects more than 15% of the patients. We analyzed the clinical, histopathological, and biological features of patients with HCC to identify the predictive factors associated with cancer recurrence and survival after LT. We retrospectively analyzed 441 patients with HCC who underwent LT in our center. Overall, 70 (15.8%) of them developed HCC-R_LT. We matched them by age at transplant and etiology with 70 non-recurrent patients. A comparable cohort from the Liver Transplant Centre of Bologna served as validation. The clinical and biochemical characteristics and pre-LT criteria (Milan, Metroticket, Metroticket_AFP, and AFP model) were evaluated. Histological analysis and immunohistochemistry for angiopoietin-2 in the tumor and non-tumor tissue of explanted livers were performed. Patients' follow-up was until death, last clinical evaluation, or 31 December 2021. In patients with HCC-R_LT, the date of diagnosis of recurrence and anatomical site has been reported; if a biopsy of recurrence was available, histologic and immunohistochemical analyses were also performed. Patients were followed up for a mean period of 62.7 ± 54.7 months (median, 39 months). A higher risk of HCC-R_LT was evident for factors related indirectly (AFP) or directly (endothelial angiopoietin-2, microvascular invasion) to biological HCC aggressiveness. In multivariate analysis, only angiopoietin-2 expression was independently associated with recurrence. Extremely high levels of endothelial angiopoietin-2 expression were also found in hepatic recurrence and all different metastatic locations. In univariate analysis, MELD, Metroticket_AFP Score, Edmondson-Steiner grade, microvascular invasion, and endothelial angiopoietin-2 were significantly related to survival. In multivariate analysis, angiopoietin-2 expression, Metroticket_AFP score, and MELD (in both training and validation cohorts) independently predicted mortality. In time-dependent area under receiver operating characteristic curve analysis, the endothelial angiopoietin-2 expression had the highest specificity and sensitivity for recurrence (AUC 0.922, 95% CI 0.876-0.962, Endothelial angiopoietin-2 expression is a powerful independent predictor of post-LT tumor recurrence and mortality, highlighting the fundamental role of tumor biology in defining the patients' prognosis after liver transplantation. The great advantage of endothelial angiopoietin-2 is that it is evaluable in HCC biopsy before LT and could drive a patient's priority on the waiting list.
Sections du résumé
Background
UNASSIGNED
Though the precise criteria for accessing LT are consistently being applied, HCC recurrence (HCC-R_LT) still affects more than 15% of the patients. We analyzed the clinical, histopathological, and biological features of patients with HCC to identify the predictive factors associated with cancer recurrence and survival after LT.
Methods
UNASSIGNED
We retrospectively analyzed 441 patients with HCC who underwent LT in our center. Overall, 70 (15.8%) of them developed HCC-R_LT. We matched them by age at transplant and etiology with 70 non-recurrent patients. A comparable cohort from the Liver Transplant Centre of Bologna served as validation. The clinical and biochemical characteristics and pre-LT criteria (Milan, Metroticket, Metroticket_AFP, and AFP model) were evaluated. Histological analysis and immunohistochemistry for angiopoietin-2 in the tumor and non-tumor tissue of explanted livers were performed. Patients' follow-up was until death, last clinical evaluation, or 31 December 2021. In patients with HCC-R_LT, the date of diagnosis of recurrence and anatomical site has been reported; if a biopsy of recurrence was available, histologic and immunohistochemical analyses were also performed.
Results
UNASSIGNED
Patients were followed up for a mean period of 62.7 ± 54.7 months (median, 39 months). A higher risk of HCC-R_LT was evident for factors related indirectly (AFP) or directly (endothelial angiopoietin-2, microvascular invasion) to biological HCC aggressiveness. In multivariate analysis, only angiopoietin-2 expression was independently associated with recurrence. Extremely high levels of endothelial angiopoietin-2 expression were also found in hepatic recurrence and all different metastatic locations. In univariate analysis, MELD, Metroticket_AFP Score, Edmondson-Steiner grade, microvascular invasion, and endothelial angiopoietin-2 were significantly related to survival. In multivariate analysis, angiopoietin-2 expression, Metroticket_AFP score, and MELD (in both training and validation cohorts) independently predicted mortality. In time-dependent area under receiver operating characteristic curve analysis, the endothelial angiopoietin-2 expression had the highest specificity and sensitivity for recurrence (AUC 0.922, 95% CI 0.876-0.962,
Conclusions
UNASSIGNED
Endothelial angiopoietin-2 expression is a powerful independent predictor of post-LT tumor recurrence and mortality, highlighting the fundamental role of tumor biology in defining the patients' prognosis after liver transplantation. The great advantage of endothelial angiopoietin-2 is that it is evaluable in HCC biopsy before LT and could drive a patient's priority on the waiting list.
Identifiants
pubmed: 36158651
doi: 10.3389/fonc.2022.960808
pmc: PMC9493368
doi:
Types de publication
Journal Article
Langues
eng
Pagination
960808Informations de copyright
Copyright © 2022 Lasagni, Leonardi, Pivetti, Di Marco, Ravaioli, Serenari, Gitto, Critelli, Milosa, Romanzi, Mancarella, Dituri, Riefolo, Catellani, Magistri, Romagnoli, Celsa, Enea, de Maria, Schepis, Colecchia, Cammà, Cescon, d’Errico, di Benedetto, Giannelli, Martinez-Chantar and Villa.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Hepat Oncol. 2019 Jun 04;6(2):HEP12
pubmed: 31205678
Breast Cancer Res Treat. 2017 Feb;162(1):191-198
pubmed: 28062977
Gastroenterology. 2012 Oct;143(4):986-94.e3; quiz e14-5
pubmed: 22750200
J Clin Pathol. 2003 Nov;56(11):854-60
pubmed: 14600132
Liver Transpl. 2007 Apr;13(4):543-51
pubmed: 17394152
Medicina (Kaunas). 2021 Nov 01;57(11):
pubmed: 34833409
Gut. 2016 May;65(5):861-9
pubmed: 25666192
Front Med (Lausanne). 2017 Nov 10;4:193
pubmed: 29209611
World J Gastroenterol. 2015 Oct 21;21(39):11185-98
pubmed: 26494973
Int J Gen Med. 2021 Sep 11;14:5563-5571
pubmed: 34539186
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428
Am J Transplant. 2017 Jan;17 Suppl 1:174-251
pubmed: 28052604
Hepatology. 2018 Sep;68(3):1010-1024
pubmed: 29604220
Cell Death Dis. 2017 Aug 24;8(8):e3017
pubmed: 28837142
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e355-e362
pubmed: 35048647
Hepatology. 2001 Jun;33(6):1394-403
pubmed: 11391528
Gastroenterology. 2018 Jan;154(1):128-139
pubmed: 28989060
J Biol Chem. 2004 Mar 26;279(13):12171-80
pubmed: 14702352
Gastroenterology. 2017 Mar;152(4):812-820.e5
pubmed: 27889576
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Cancer. 1954 May;7(3):462-503
pubmed: 13160935
Lancet Oncol. 2009 Jan;10(1):35-43
pubmed: 19058754
J Cell Physiol. 2008 Feb;214(2):491-503
pubmed: 17960565
Clin Biochem. 2018 Feb;52:20-25
pubmed: 29054441
Front Oncol. 2020 Feb 28;10:171
pubmed: 32185125
Nat Rev Cancer. 2014 Sep;14(9):611-22
pubmed: 25118602
J Clin Gastroenterol. 2008 Aug;42(7):839-43
pubmed: 18668703
J Hepatol. 2009 May;50(5):923-8
pubmed: 19303163